6855 — Ascentage Pharma International Share Price
0.000.00%
Last trade - 00:00- HK$13.53bn
- HK$14.18bn
- CNY221.98m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 16.46 | ||
| Price to Tang. Book | 19.06 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 13.97 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -14.33% | ||
| Return on Equity | -53.13% | ||
| Operating Margin | -32.4% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 14.51 | 12.45 | 27.91 | 209.71 | 221.98 | 927.63 | 526.65 | 100.76% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ascentage Pharma Group International is a holding company primarily engaged in discovering, developing and commercializing therapies primarily in hematological malignancies. The Company’s main business is engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus and certain age-related diseases. The Company’s main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918 and other products. The Company’s products are mainly used to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. The Company mainly conducts its business in the domestic market.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- November 17th, 2017
- Public Since
- October 28th, 2019
- No. of Employees
- 574
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 348,266,581
- Address
- 68 Xinqing Road, Suzhou Industrial Park, Suzhou
- Web
- https://www.ascentage.cn/
- Phone
- Auditors
- Ernst & Young
Upcoming Events for 6855
Similar to 6855
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Beigene
Stock Exchange of Hong Kong Limited
FAQ
What is the Ascentage Pharma International share price?
As of Today at 18:21 UTC, shares in Ascentage Pharma International are trading at HK$38.85. This share price information is delayed by 15 minutes.
How has the Ascentage Pharma International share price performed this year?
Shares in Ascentage Pharma International last closed at HK$38.85 and the price had moved by +68.18% over the past 365 days. In terms of relative price strength the Ascentage Pharma International share price has outperformed the FTSE Developed Asia Pacific Index by +72.24% over the past year.
What are the analyst and broker recommendations for Ascentage Pharma International?
The overall consensus recommendation for Ascentage Pharma International is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Ascentage Pharma International dividend yield?
Ascentage Pharma International does not currently pay a dividend.
Does Ascentage Pharma International pay a dividend?
Ascentage Pharma International does not currently pay a dividend.
When does Ascentage Pharma International next pay dividends?
Ascentage Pharma International does not currently pay a dividend.
How do I buy Ascentage Pharma International shares?
To buy shares in Ascentage Pharma International you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ascentage Pharma International?
As of the previous close price of HK$38.85, shares in Ascentage Pharma International had a market capitalisation of HK$13.53bn.
Where are Ascentage Pharma International shares listed?
Here are the trading details for Ascentage Pharma International:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 6855
What kind of share is Ascentage Pharma International?
Based on an overall assessment of its quality, value and momentum Ascentage Pharma International is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ascentage Pharma International share price forecast for 2025?
The analyst consensus target price for shares in Ascentage Pharma International is HK$51.52. That is 32.6% above the last closing price of HK$38.85.
Analysts covering Ascentage Pharma International currently have a consensus Earnings Per Share (EPS) forecast of -CNY1.07 for the next financial year.
Find out moreWhat is the trend in the Ascentage Pharma International share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ascentage Pharma International. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +22.26%.
As of the last closing price of HK$38.85, shares in Ascentage Pharma International were trading +11.52% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ascentage Pharma International PE Ratio?
The Ascentage Pharma International PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$38.85.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ascentage Pharma International?
We do not have data on Ascentage Pharma International's directors